We can’t show the full text here under this license. Use the link below to read it at the source.
Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world retrospective administrative database analysis in Japan
Fewer heart problems in type 2 diabetes patients taking SGLT2 inhibitors compared to DPP-4 inhibitors in Japan
AI simplified
Abstract
were associated with a significant reduction in hospitalization for heart failure risk among patients with type 2 diabetes without a cardiovascular disease history.
- SGLT2 inhibitors were linked to a reduction in all-cause death risk compared to .
- The composite risk of hospitalization for heart failure or all-cause death was also lower with SGLT2 inhibitors.
- Significant risk reductions were observed in the full cohort, as well as in patients both with and without a cardiovascular disease history.
- No significant reduction in hospitalization for heart failure was found in patients with a cardiovascular disease history.
AI simplified
Key numbers
0.507
Reduction in heart failure hospitalization risk
Hazard ratio for hHF in patients without
0.592
Reduction in all-cause death risk
Hazard ratio for ACD in the full cohort
0.712
Reduction in composite risk of hHF or ACD
Hazard ratio for composite events in the full cohort